

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 3. (Cancelled)
4. (Withdrawn) A method of determining the efficacy of an anti-cancer therapeutic agent comprising the steps of; providing a cell sample; contacting the cell sample with an oncoprotein; contacting the sample with the anti-cancer therapeutic agent; and assaying the sample to determine the presence of the oncoprotein binding to the cellular DNA, whereby the down-regulation of the oncoprotein binding to the cellular DNA indicates the therapeutic agent possesses anti-tumorogenic properties.
5. (Withdrawn) The method of claim 4 wherein the oncoprotein is Oct-1
6. (Withdrawn) A method of determining the role of a protein of interest as an oncoprotein comprising the steps of; providing a cell line which constitutively expresses the protein of interest; transfecting the cell line with a vector containing an antisense strand to the protein of interest; culturing the cell line for a predetermined amount of time; and assaying the cell for the expression of oncogenic characteristics, whereby the loss of oncogenic characteristics, as compared to control transformants, indicated the protein of interest is an oncoprotein.
7. (Withdrawn) The method of claim 6 wherein the cell line is Rb-defective.
8. (Withdrawn) The method of claim 6 wherein the vector is pcDNA3.
9. (New) A method for treating a tumor in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an Oct-1 inhibitor.
10. (New) The method of claim 9 wherein an Oct-1 inhibitor inhibits Oct-1 binding activity.
11. (New) the method of claim 9 wherein an Oct-1 inhibitor inhibits Oct-1 mRNA function.
12. (New) The method of claim 9 wherein the an Oct-1 inhibitor is a vector containing an Oct-1 antisense sequence.
13. (New) The method of claim 9 wherein the an Oct-1 inhibitor is an RNA inhibitor molecule.

If the Office is not fully persuaded that this amendment document submitted meets the requirements under 37 CFR 1.121, a telephone call to the undersigned at (813) 925-8505 is requested.

Very respectfully,

SMITH & HOPEN

Dated: June 14, 2006

By: 


Thomas E Toner
Reg. No. 57,422
180 Pine Avenue North
Oldsmar, Florida 34677
Attorneys for Applicant

CERTIFICATE OF FACSIMILE TRANSMISSION

(37 C.F.R. 1.8(a))

I HEREBY CERTIFY that this response to the Notice of Non-Compliant Amendment, Amendments to the Claims is being transmitted by facsimile to the United States Patent & Trademark Office Art Unit 1635, Attn: Tracey Ann Vivlemore (571) 273-8300 on June 14, 2006.

Dated: June 14, 2006


Charlene Morgan